Proactive Investors - Run By Investors For Investors

Rhinomed to launch vapour release technology after securing US purchase orders

The company will showcase its Pronto technology at the American Academy of Sleep Medicine Meeting in San Antonio, Texas, in June.
Rhinomed products
The launch represents a major milestone and expansion of the Rhinomed nasal platform

Rhinomed Ltd (ASX:RNO) is set to launch its revolutionary ProntoTM rechargeable vapour release technology in the second half of 2019 targeting sleep and decongestion.

This follows the receipt of initial purchase orders from one of the USA’s leading drug store chains.

Pronto comes in two formulation variants - Pronto Sleep and Pronto Clear - aimed at addressing unmet needs in the US$49 billion global sleep aid market and US$34 billion global nasal congestion, cough, cold and allergy market.

Initial purchase orders

The initial purchase orders for the Pronto Sleep aid product have been received from one of America’s leading drugstore chains with product shipping scheduled for the end of May 2019 for more than 2,800 packs, which will be rolled out into 900 stores.

This purchase order is also from a stockist of the company's Mute technology.

Based on stenting technology

Based on the company’s existing BreatheAssistTM stenting technology, which has seen the release of two variants MuteTM and TurbineTM, the new Pronto range includes the novel AirstreamTM release system.

This allows a specific amount of a formulation to be released into the nasal airstream over a set period of time.

By combining this new vapour release technology with the Mute’s stenting action, Rhinomed provides users with a unique dual action medical device that not only improves nasal airflow, but also delivers the associated benefits of the specific formulation.

"World leading investor"

Rhinomed chief executive officer Michael Johnson said: “Rhinomed is delivering on its potential as a world-leading investor in the nasal, respiratory, sleep and drug delivery markets.

“We have become one of those rare Australian companies that has not only developed a technology but has also now proven consumer and clinical adoption, established global distribution and shelf presence and established a product that is now one of the fastest growing brands in its category.

“Mute has now successfully delivered millions of nights of better sleep to customers across three continents – it's time we start leveraging our platform to deliver drugs and formulations into specific target markets.”

View full RNO profile View Profile

Rhinomed Ltd Timeline

Newswire
September 16 2015

Related Articles

Cancer cells
February 12 2019
The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise
scientist in lab
February 25 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year
1550850611_CancerHeadline.jpg
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use